Home Alzheimer’s Disease Initial Ibrutinib Dose and Its Modification Do Not Affect Survival in Patients...

Initial Ibrutinib Dose and Its Modification Do Not Affect Survival in Patients with CLL

In a study published in Cancer Medicine, researchers found that in a large cohort of patients with chronic lymphocytic leukemia (CLL) receiving commercial ibrutinib (Imbruvica), initial ibrutinib dose and dose modification during therapy did not appear to impact event-free survival (EFS) or overall survival (OS).

These findings highlighted the challenges associated with continuous oral therapy with ibrutinib in patients with CLL. The results also confirmed observations from other “real-world” analyses that more patients stop ibrutinib due to toxicity rather than due to progression of disease. 

“This latter finding has major implications for clinical trial design where combination therapies with fixed duration of treatment that achieve deep remission may be more desirable than chronic long-term treatment,” the authors wrote. 

Conducting a retrospective study of patients…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalition Network...

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

Recent Comments